2022
NAFTNet retrospective report on the treatment of anti-Ro/SSA mediated fetal heart block with dexamethasone
Sunderji S, Peyvandi S, Jaeggi E, Szwast A, Ryan G, Tessier F, Siddiqui S, Cuneo B, Sheth S, Treadwell M, Frommelt M, Turan S, Copel J, Emery S, Rand L, Moon-Grady AJ, Network F. NAFTNet retrospective report on the treatment of anti-Ro/SSA mediated fetal heart block with dexamethasone. The Journal Of Maternal-Fetal & Neonatal Medicine 2022, 35: 9263-9270. PMID: 35014577, DOI: 10.1080/14767058.2022.2025536.Peer-Reviewed Original ResearchConceptsPositive pregnanciesPrimary outcomePregnancy complicationsPregnancy outcomesPremature deliverySecondary outcomesNorth American Fetal Therapy Network (NAFTNet) centersRo/SSA-positive pregnanciesRetrospective multi-center cohort studyAnti-Ro/SSAMulti-center cohort studyFetal heart blockOverall pregnancy complicationsBetter pregnancy outcomesPoor pregnancy outcomesUse of dexamethasoneTerms of efficacyHigh rateFetal dyadsMaternal comorbiditiesAntibody positivityExpectant managementMaternal diseaseNeonatal morbidityPreterm delivery
2012
Evaluating the cost‐effectiveness of prenatal surgery for myelomeningocele: a decision analysis
Werner E, Han C, Burd I, Lipkind H, Copel J, Bahtiyar M, Thung S. Evaluating the cost‐effectiveness of prenatal surgery for myelomeningocele: a decision analysis. Ultrasound In Obstetrics And Gynecology 2012, 40: 158-164. PMID: 22511529, DOI: 10.1002/uog.11176.Peer-Reviewed Original ResearchConceptsPrenatal myelomeningocele repairQuality-adjusted life yearsMyelomeningocele repairPostnatal repairMyelomeningocele patientsPrenatal surgeryAdditional casesLong-term medical careFuture pregnancy complicationsIncremental cost-effectiveness ratioPostnatal myelomeningocele repairCost-effectiveness ratioDecision analysis modelingUterine ruptureNeurologic deficitsPregnancy complicationsSingleton gestationsSurgery resultsLife yearsMedical carePatientsCost-effective strategyNormal karyotypeNeonatesSurgery